Nadifloxacin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Nadifloxacin: From Acne to Malaria
One-Sentence Summary
Nadifloxacin is a topical fluoroquinolone antibacterial originally used to treat acne. The TxGNN model predicts it may be effective for malaria, but no clinical trials and no publications currently support this prediction. It is a model-based hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acne |
| Predicted New Indication | Malaria |
| TxGNN Prediction Score | 0.9916 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, nadifloxacin is a topical fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Its efficacy in acne is attributed to its antibacterial action.
A theoretical link to malaria exists: Plasmodium has a gyrase located in its apicoplast, which could in principle be a target for quinolones. However, this is a hypothesis with no supporting activity data. The very high TxGNN score (0.9916) reflects a model prediction only.
A major unresolved concern is route of administration. Nadifloxacin is marketed only as topical products (cream, gel, ointment, dusting powder), and achieving systemic antimalarial exposure with these forms is doubtful. Malaria is a bloodstream infection.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
All 20 registrations are valid single-ingredient products. The five main ones are shown below. Approved indication text is not available in the data compiled for this report.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| 156062 | Nadoxin 1% Dusting Powder | 10 gm packet, dusting powder | Dr Reddy’s Laboratories Ltd |
| 215775 | Triclear N Gel | 20 gm tube, gel | Trikona Pharmaceuticals Pvt. Ltd. |
| 155357 | Nadikem Cream | 20 gm tube, cream | Alkem Laboratories Ltd |
| 150775 | Nadoxin-A Gel | 15 gm tube, gel | Dr Reddy’s Laboratories Ltd |
| 151528 | Nadimax Cream | 15 gm tube, cream | Zee Laboratories |
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The malaria prediction rests only on a model score, with no clinical trials or literature. The available products are topical, which makes systemic antimalarial exposure unlikely.
To proceed, the following is needed:
- Mechanism of action data for nadifloxacin
- In vitro activity data against Plasmodium (and, as secondary candidates, Leishmania and Borrelia)
- Pharmacokinetic evidence on whether therapeutic systemic exposure is achievable, or a feasibility assessment for a non-topical formulation
- Package insert warnings and contraindications from the Indian regulatory source
- A systematic literature and trial search for malaria and the other top-ranked predicted indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.